Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.
Pires LA, Abraham WT, Young JB, Johnson KM; MIRACLE and MIRACLE-ICD Investigators. Pires LA, et al. Among authors: young jb. Am Heart J. 2006 Apr;151(4):837-43. doi: 10.1016/j.ahj.2005.06.024. Am Heart J. 2006. PMID: 16569543
Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.
Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Young JB, et al. JAMA. 2003 May 28;289(20):2685-94. doi: 10.1001/jama.289.20.2685. JAMA. 2003. PMID: 12771115 Clinical Trial.
Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure.
Abraham WT, Young JB, León AR, Adler S, Bank AJ, Hall SA, Lieberman R, Liem LB, O'Connell JB, Schroeder JS, Wheelan KR; Multicenter InSync ICD II Study Group. Abraham WT, et al. Among authors: young jb. Circulation. 2004 Nov 2;110(18):2864-8. doi: 10.1161/01.CIR.0000146336.92331.D1. Epub 2004 Oct 25. Circulation. 2004. PMID: 15505095 Clinical Trial.
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
O'Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E, Granger C, Olofsson B, Young JB, Swedberg K. O'Meara E, et al. Among authors: young jb. Eur Heart J. 2004 Nov;25(21):1920-6. doi: 10.1016/j.ehj.2004.07.025. Eur Heart J. 2004. PMID: 15522471 Clinical Trial.
786 results